Skip to main content

Table 3 BiTes currently in FL trials

From: Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

BiTe

NCT#/publication

Route/Administration schedule

Phase

Total n [FL]

Median lines of prior therapy

% POD24

ORR%a [CR%]

mPFS

CRS % [G ≥ 3]

Neuro % [G ≥ 3]

Approved

Mosunetuzumab

[96]

IV Qweekly for cycle 1, Q21 days for cycles ≥ 2, stopped after cycle 8 for CR

1

62 [62]

3

48

68 [50]

11.8

2

0

Odronextumab

[97]

IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36

1

96 [25]

3

NP

93 [71]

NP

7

3

Odronextumab

NCT03888105 [98]

IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36

II

NAb

NAb

NAb

NAb

NAb

NAb

NAb

Epcoritamab

[100]

sq Qweekly C1-2, Q2 weeks C3-6, Q4 weeks thereafter, 28 day cycles

I

67 [12]

3

NP

100 [25]

NP

0

3

Glofitamab

[108]

Obinutuzumab on D-7, weekly for two weeks then Q2 weeks for 28 weeks

I

171 [44]

3

NP

62 [52]c

11.8

3.5

1.2

  1. Abbreviations: CRS—cytokine release syndrome; CR—complete response rate; Neuro—neurotoxicity; NP—not presented; ORR—overall response rate; PFS—progression-free survival; POD24—progression of disease within 24 months following chemoimmunotherapy; sq—subcutaneous; Qweekly—every week; Q2 weeks—every 2 weeks
  2. aResponse rates in FL subset
  3. bNot available, clinical trial is ongoing
  4. cfor cohorts receiving ≥ 10 mg dosing